Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States
Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service company in healthcare, has been included as a supplier to a major medical system covering 60,000 care providers across 400 hospitals and 400 care centers in 21 states. This partnership aims to address the significant gap in cardiovascular care accessibility in the U.S., where 121.5 million adults have some form of cardiovascular disease, and nearly half of U.S. counties lack a practicing cardiologist.
Biotricity offers Biocore, the world's only 3-lead compact connected cardiac monitoring device, known for its superior diagnostic yield. The company's solutions are currently used by over 2,500 cardiologists in more than 500 locations. This new inclusion is expected to expand Biotricity's market reach and accelerate its path to profitability.
Biotricity Inc. (OTCQB:BTCY), un'azienda leader nel settore Technology-as-a-Service in ambito sanitario, è stata inclusa come fornitore di un importante sistema medico che copre 60.000 fornitori di assistenza in 400 ospedali e 400 centri di cura in 21 stati. Questa partnership mira a colmare il significativo divario nell'accessibilità alle cure cardiovascolari negli Stati Uniti, dove 121,5 milioni di adulti soffrono di qualche forma di malattia cardiovascolare e quasi la metà delle contee statunitensi non ha un cardiologo praticante.
Biotricity offre Biocore, l'unico dispositivo di monitoraggio cardiaco connesso a 3 elettrodi al mondo, noto per il suo eccezionale rendimento diagnostico. Le soluzioni dell'azienda sono attualmente utilizzate da oltre 2.500 cardiologi in più di 500 sedi. Questa nuova inclusione dovrebbe ampliare la portata di mercato di Biotricity e accelerare il suo percorso verso la redditività.
Biotricity Inc. (OTCQB:BTCY), una empresa líder en el sector de Technology-as-a-Service en el ámbito de la salud, ha sido incluida como proveedor de un importante sistema médico que abarca 60,000 proveedores de atención en 400 hospitales y 400 centros de atención en 21 estados. Esta asociación tiene como objetivo abordar la significativa brecha en el acceso a la atención cardiovascular en EE. UU., donde 121.5 millones de adultos padecen alguna forma de enfermedad cardiovascular, y casi la mitad de los condados de EE. UU. carecen de un cardiólogo en ejercicio.
Biotricity ofrece Biocore, el único dispositivo de monitoreo cardíaco conectado de 3 electrodos en el mundo, conocido por su superior rendimiento diagnóstico. Las soluciones de la empresa son utilizadas actualmente por más de 2,500 cardiólogos en más de 500 ubicaciones. Se espera que esta nueva inclusión expanda el alcance de mercado de Biotricity y acelere su camino hacia la rentabilidad.
Biotricity Inc. (OTCQB:BTCY)는 헬스케어 분야에서 Technology-as-a-Service의 선두주자로서, 주요 의료 시스템의 공급자로 포함되었습니다. 이 시스템은 21개 주의 400개 병원과 400개의 치료 센터, 60,000명의 치료 제공자를 커버합니다. 이 파트너십의 목표는 미국에서 심혈관 치료 접근성의 중대한 격차를 해소하는 것입니다. 미국에서는 1억 2150만 명의 성인이 심혈관 질환의 어떤 형태를 겪고 있으며, 거의 절반의 카운티에는 활동 중인 심장 전문의가 없습니다.
Biotricity는 세 개의 리드가 연결된 세계 유일의 콤팩트한 심장 모니터링 장치인 Biocore를 제공합니다, 뛰어난 진단 성능으로 알려져 있습니다. 회사의 솔루션은 현재 500개 이상의 위치에서 2,500명 이상의 심장 전문의에 의해 사용되고 있습니다. 이번 새로운 포함은 Biotricity의 시장 범위를 확대하고 수익성으로 가는 길을 가속화할 것으로 예상됩니다.
Biotricity Inc. (OTCQB:BTCY), une entreprise leader dans le secteur de la Technology-as-a-Service en soins de santé, a été incluse comme fournisseur d'un système médical majeur couvrant 60 000 fournisseurs de soins à travers 400 hôpitaux et 400 centres de soins dans 21 États. Ce partenariat vise à combler le fossé significatif en matière d'accès aux soins cardiovasculaires aux États-Unis, où 121,5 millions d'adultes souffrent d'une forme de maladie cardiovasculaire, et près de la moitié des comtés américains n'ont pas de cardiologue en exercice.
Biotricity propose Biocore, le seul dispositif de surveillance cardiaque connecté à 3 électrodes au monde, connu pour son rendement diagnostic supérieur. Les solutions de l'entreprise sont actuellement utilisées par plus de 2 500 cardiologues dans plus de 500 lieux. Cette nouvelle inclusion devrait élargir la portée du marché de Biotricity et accélérer son chemin vers la rentabilité.
Biotricity Inc. (OTCQB:BTCY), ein führendes Unternehmen im Bereich Technology-as-a-Service im Gesundheitswesen, wurde als Anbieter eines großen medizinischen Systems aufgenommen, das 60.000 Dienstleister in 400 Krankenhäusern und 400 Pflegezentren in 21 Bundesstaaten abdeckt. Diese Partnerschaft zielt darauf ab, die erhebliche Lücke im Zugang zur kardiovaskulären Versorgung in den USA zu schließen, wo 121,5 Millionen Erwachsene an irgendeiner Form von Herz-Kreislauf-Erkrankung leiden und fast die Hälfte der US-Countys über keinen praktizierenden Kardiologen verfügt.
Biotricity bietet Biocore, das weltweit einzige kompakte, mit drei Elektroden verbundene Herzmonitor-Gerät, das für seine überlegene diagnostische Ausbeute bekannt ist. Die Lösungen des Unternehmens werden derzeit von über 2.500 Kardiologen an mehr als 500 Standorten eingesetzt. Diese neue Aufnahme wird voraussichtlich die Marktreichweite von Biotricity erweitern und den Weg zur Rentabilität beschleunigen.
- Inclusion as a supplier to a major medical system covering 60,000 care providers
- Expansion of market reach to 400 hospitals and 400 care centers across 21 states
- Potential acceleration of path to profitability
- Current usage of Biotricity solutions by over 2,500 cardiologists in 500+ locations
- None.
REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease. Yet nearly half of U.S. counties do not have a practicing cardiologist, leaving patients in these areas with a roundtrip of over 85 miles to see a heart specialist versus 16 miles for those in a county with at least 1 cardiologist.
"At Biotricity, we're dedicated to closing the wide gap in cardiovascular care across the nation," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "Our inclusion as a supplier to this prominent medical system represents a significant step forward in ensuring that our innovative solutions are accessible to providers and patients. We're committed to transforming the landscape of healthcare delivery to improve patient outcomes, especially in underserved communities. As rollouts like this occur, Biotricity's path to profitability will accelerate."
Biotricity offers the only 3-lead compact connected cardiac monitoring device in the world- Biocore. Biocore is small in size and large in data, with the best diagnostic yield in the industry to minimize patient risk and optimize outcomes. The company's solutions are trusted by over 2,500 cardiologists in over 500 locations. This partnership not only expands Biotricity's market reach but also underscores its commitment to addressing critical gaps in cardiovascular care across the nation. For more information about Biotricity and its innovative healthcare solutions, please visit Biotricity.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Biotricity Investor Relations:
Investors@biotricity.com
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
FAQ
What is Biotricity's latest partnership announcement?
What is Biotricity's main product for cardiac monitoring?
How many cardiologists currently use Biotricity's solutions?
How does this partnership affect Biotricity's (BTCY) profitability?
